Definium Therapeutics (DFTX) Total Non-Current Liabilities (2020 - 2026)

Definium Therapeutics (DFTX) has 7 years of Total Non-Current Liabilities data on file, last reported at $121.9 million in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 251.54% year-over-year to $121.9 million in Q1 2026; TTM through Mar 2026 was $121.9 million, a 251.54% increase from a year earlier, with the FY2025 full-year figure at $107.3 million, up 201.81% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $121.9 million, up from $107.3 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for DFTX reached as high as $121.9 million in Q1 2026 and fell as low as $7.9 million in Q2 2022.
• Historically, Total Non-Current Liabilities has averaged $51.7 million across 5 years, with a median of $35.5 million in 2024.
• Across the five-year window, Total Non-Current Liabilities soared 346.21% in 2023 and tumbled 56.36% in 2025, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $17.9 million in 2022, then soared by 159.19% to $46.4 million in 2023, then dropped by 23.35% to $35.5 million in 2024, then jumped by 201.81% to $107.3 million in 2025, then climbed by 13.62% to $121.9 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $121.9 million in Q1 2026, $107.3 million in Q4 2025, and $105.8 million in Q3 2025.